On 5 August 2026, the UK's Medical Research Council (MRC) announced a £50 million investment in mitochondrial disease research. The funding will support the new MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics, a Cambridge-led programme focused on moving from an understanding of disease-causing mutations towards therapies. UK Research and Innovation details the funding and the centre's remit.
Why mitochondrial DNA remains difficult to treat
The centre will address a question that still limits treatment: how do mutations in mitochondrial DNA cause disease? Experts from several disciplines will work on that problem, with the stated aim of translating the resulting knowledge into therapies.
The need is substantial. Mitochondrial diseases are genetic disorders that affect about one in 5,000 people. Mitochondrial DNA mutations are increasingly associated with neurodegeneration, metabolic disease, cardiovascular failure and age-related deterioration. Mitochondrial dysfunction can contribute to severe disability, progressive decline and premature death.
No curative treatment currently exists for these diseases. That makes the new centre relevant to affected families, but the announcement describes a research programme rather than a treatment ready for patients.
Genome tools and advanced disease models
The centre plans to use emerging technologies to modify the mitochondrial genome and create advanced models of frequent pathogenic mitochondrial DNA mutations. These models are intended to help researchers investigate mutations that are most relevant to disease as part of the wider effort to develop therapies.
The immediate change is therefore in the organisation and scale of the research. The programme brings genome-modification technologies, disease models and specialists from several institutions into one Cambridge-led effort. Its success will still depend on whether those research advances can eventually be translated into effective therapies.
An international partnership
The University of Cambridge will lead the centre alongside the universities of Birmingham, Manchester, Heidelberg and Queensland, as well as the Imagine Institute in Paris. The partnership will also include charities, including the Lily Foundation, and companies from around the world.
The Lily Foundation says its role includes bringing families' priorities into the research and investing in the next generation of scientists. That gives the programme a direct link to patient priorities and future research capacity, alongside its scientific work.
What the funding does not change
The MRC says the UK contributed to the development of mitochondrial replacement therapy, which prevents the transmission of mitochondrial DNA mutations. That achievement provides relevant context for the country's work in this field, but it does not mean that a cure now exists for people already affected by mitochondrial disease.
For those families, the meaningful result will come later if the coordinated research produces effective therapies. For now, the £50 million investment expands the effort to understand the mutations behind these disorders while the treatment gap remains. The centre marks a larger and more coordinated research push, not an immediate change in the care available to patients.
